{"id":"W4308260067","doi":"10.1038/s41416-022-02025-9","title":"A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer","year":2022,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":34,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Pfizer","keywords":"Tolerability; Medicine; Mucositis; Docetaxel; Internal medicine; Response Evaluation Criteria in Solid Tumors; Breast cancer; Triple-negative breast cancer; Oncology; Cancer; Phases of clinical research; Adverse effect; Gastroenterology; Chemotherapy; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001077693,0.001788832,0.00219851,0.00055013,0.0004734963,0.001225365,0.0008783441,0.001670201,0.008293488],"category_scores_gemma":[0.000647514,0.0009109661,0.00159928,0.0004927546,0.001145202,0.001119271,0.0003633094,0.004365156,0.001945549],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001249223,"about_ca_system_score_gemma":0.001599678,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001622221,"about_ca_topic_score_gemma":0.005471137,"domain_scores_codex":[0.9997167,0.0001005667,0.000009524539,0.00005726333,0.00002529348,0.00009063827],"domain_scores_gemma":[0.9996189,0.00005191976,0.00005245673,0.00003067428,0.00002360994,0.000222495],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7340327,0.0859409,0.002618416,0.001308634,0.001721082,0.0003209788,0.0002871484,0.004327417,0.04545613,0.0008504717,0.01268434,0.1104518],"study_design_scores_gemma":[0.6683288,0.3146149,0.005365787,0.00004648613,0.0003869397,0.0003747331,0.00007883176,0.001480858,0.002603399,0.000399614,0.006268704,0.00005096756],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9820359,0.004018814,0.00102844,0.001426682,0.0004859661,0.002975304,0.003109646,0.0002656549,0.004653554],"genre_scores_gemma":[0.9752609,0.003823279,0.002626554,0.001824599,0.0002568477,0.003070201,0.004847293,0.00007344859,0.008216958],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008293488,"threshold_uncertainty_score":0.02774447,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01529950966336782,"score_gpt":0.3277349865391015,"score_spread":0.3124354768757337,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}